SCHEMBL6832124

SCHEMBL6832124

COCOc1c(C)cccc1C(C)(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
PTPN1 P18031 1/20 0.50
KDM4E B2RXH2 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
GAA P10253 1/20 0.45
GABRA1 P14867 1/20 0.44
GABRB2 P47870 1/20 0.44
SCN2A Q99250 3/20 0.40
NLRP3 Q96P20 1/20 0.38
SCN4A P35499 6/20 0.37
LMNA P02545 2/20 0.37
SCN1A P35498 2/20 0.37
SCN5A Q14524 2/20 0.37
SCN9A Q15858 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
TSHR P16473 1/20 0.37
NFKB1 P19838 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24823151 0.83 ALDH1A1 (0.51) ALDH1A1PTPN1KDM4ESMN1; SMN2GAA
SCHEMBL13594738 0.82 PTPN1 (0.61) ALDH1A1PTPN1KDM4ESCN2ASCN4A
SCHEMBL12772148 0.81 ALDH1A1 (0.36) ALDH1A1PTPN1KDM4ESMN1; SMN2GAA
SCHEMBL11646260 0.79 GABRA1 (0.52) ALDH1A1KDM4ESMN1; SMN2GAAGABRA1
SCHEMBL12843836 0.79 PTPN1 (0.42) ALDH1A1PTPN1KDM4ESMN1; SMN2GAA
SCHEMBL73389 0.79 ALDH1A1 (0.61) ALDH1A1KDM4ESMN1; SMN2GAAGABRA1
SCHEMBL16479215 0.79 ALDH1A1 (0.61) ALDH1A1KDM4ESMN1; SMN2GAAGABRA1
SCHEMBL9186079 0.79 ALDH1A1 (0.54) ALDH1A1KDM4ESMN1; SMN2GAAGABRA1
SCHEMBL1728866 0.78 PIM1 (0.44) ALDH1A1PTPN1KDM4ESMN1; SMN2GAA
SCHEMBL11333666 0.77 ALDH1A1 (0.60) ALDH1A1KDM4ESMN1; SMN2GAAGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6743923-B2 A BENZYLIDENE DERIVATIVES USED FOR OSTEOCLAST FORMATION INHIBITION, A NITROGEN MONOXIDE PRODUCTION INHIBITION, AND A TRANSCRIPTION FACTOR NF KAPPA B SUPRESSING AGENT SHIONOGI & CO., LTD. (JP) 2004-06-01 US disclosed
US-20030125364-A1 Antirheumatic agent MATSUMOTO SAICHI (JP) 2003-07-03 US disclosed
US-6525081-B1 Inhibiting osteoclast formation and nitrogen monoxide production; suppressing transcription factor NF kappa B SHIONOGI & CO., LTD. (JP) 2003-02-25 US disclosed
EP-1026162-A1 ANTIRHEUMATIC SHIONOGI & CO., LTD. (JP) 2000-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125364-A1 Antirheumatic agent IL1A, IL1B, IL17A ALDH1A1 236/4885PTPN1 2724/4885KDM4E 3480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.